Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. We hypothesize that Onconase exerts an effect via downregulation of nuclear factor kappa B (NFKb) by specific microRNAs (miRNAs) and that interference of this pathway could have implications for MPM resistance to chemotherapy. Three immortalized MPM cell lines (H2959, H2373 and H2591) were exposed to Onconase at 0-20 lg/ml. Cell counts were measured at 48 and 72 h. Gene expression in miRNA-enriched RNA was validated by reverse transcription-PCR (RT-PCR). The functional implications of miRNA expression were evaluated by transfecting miRNA mimics or inhibitors into MPM cell lines, and performing Matrigel invasion, cell proliferation, soft agar colony formation and scratch closure assays. Effects on NFKb expression and downstream targets including ABC transporters, BCL-xl and IAP were assessed by RT-PCR and western blotting. Treatment with 20 lg/ml of Onconase significantly decreased cell count and invasion. Hsa-miR-17* was significantly upregulated and hsamiR-30c was significantly downregulated by Onconase treatment in all cell lines. Forced expression of hsa-miR-17* mimic and hsa-miR-30c inhibitor each significantly decreased functional activity of Onconase in all assays. NFKB1 (p50) expression and downstream targets were also decreased with Onconase treatment, as well as with forced expression of miRNA mimic and inhibitors. Onconase treatment caused a significant decrease in cell proliferation, invasion and in expression of certain miRNAs. Recapitulation of the resultant miRNA expression pattern with hsa-miR-17* mimic and hsa-miR-30c inhibitor resulted in downregulation of NFKB1 and reduced malignant behavior in functional assays. Thus, Onconase likely exerts its antitumor effect through these miRNAs.
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Introduction
Malignant pleural mesothelioma (MPM) is a rare disease with B2000-3000 new cases in the United States diagnosed annually (Kaufman and Pass, 2008) . Over the last 20 years, the incidence of MPM has steadily increased, with 70-80% of cases implicating asbestos exposure as the dominant risk factor (Robinson and Lake, 2005; Kaufman and Pass, 2008) . Management of MPM is predominately with chemotherapy and radiation due its diffuse and invasive nature, which often precludes surgical resection. Consideration for surgery either as an extrapleural pneumonectomy or pleurectomy/decortication is dependent on the disease stage, pulmonary function and surgeon experience. (Beck et al., 2008) Current first-line therapy for unresectable disease includes combination pemextred and cisplatin, a treatment plan with a high rate of failure due to chemoresistance or the presence of advanced disease (Pass et al., 2004; Pavlakis and Vogelzang, 2006; Carbone et al., 2007) . Onconase (Ranpirnase), a member of the pancreatic RNAase A superfamily of ribonucleases, is a chemotherapeutic agent which has demonstrated selective antitumor activity in a variety of human malignancies including MPM (Wu et al., 1993) . Onconase exerts its antiproliferative and cytotoxic effects by interfering with cell-cycle regulation and induction of programmed cell death and intermediates in Ranpirnase mechanism of function have been described in many publications (Lee and Raines, 2008; Porta et al., 2008) . Activation of MAPK and an increase in JNK activity was first described in HeLa cells (Iordanov et al., 2000) . Ranpirnase has been shown to activate caspase 3 and decrease Bcl2 concomitant with inducing apoptosis . Ranpirnase decreases nuclear factor kappa light-chain enhancer of activated B cells (NFkappaB, p50), a transcription factor that has also been strongly implicated in cancer cell chemoresistance, antiapoptosis and induction of cell proliferation (Ardelt et al., 2003) . Growth suppression induced by Onconase is closely coordinated with a downregulation in the steady state and subcellular distribution of NF-kappaB (Tsai et al., 2004) , In fact, the reduction of NF-kappaB expression by Onconase seems to coincide or even precede the growth suppression, which suggests a causal relationship. Onconase also enhances tumor cell sensitivity to a number of cytotoxic agents with diverse mechanisms of action, making it ideal for use in combination therapy (Mikulski et al., 1992; Rybak et al., 1996; Zhao et al., 2008) . In a recent phase-IIIb clinical trial reported at ASCO 2009, Onconase added to Doxorubicin therapy demonstrated significant efficacy in patients with MPM that failed previous chemotherapy. Median survival was prolonged in this Onconase-Doxorubicin-treated subgroup of previously treated mesothelioma patients compared with patients who received Doxorubicin alone (P ¼ 0.016) (Reck et al., 2009) .
Although it is believed that tRNA is chiefly affected by Ranpirnase, other downstream RNA species that mediate the cytotoxic effects of Onconase have not been previously described (Mikulski et al., 1992; Wu et al., 1993; Deptala et al., 1998; Zhao et al., 2008) . MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate protein-coding genes and provide insight into gene regulation and cell behavior. The relationship between Onconase treatment and miRNA and how it intermediates and controls cell proliferation, invasion, migration and apoptosis has not been investigated. Moreover, further validation of the Onconase regulation of NFKb expression and whether microRNAs influenced by Onconase are involved in this regulation remains speculative. We hypothesize that (1) Onconase exerts an effect via specific miRNAs, (2) these miRNAs will have similar effect on MM cells as Onconase itself and (3) these effects are involved in the regulation of NFKb and its downstream targets.
An elucidation of these pathways could give insight into the ability of Onconase to function as a chemosensitizing adjunctive therapy.
Results
Onconase treatment-cell count and cell functionality Cell lines were subjected to treatment with Onconase at 0-20 mg/ml. A significant decrease in cell proliferation was observed in all the three cell lines with 20 mg/ml Onconase treatment at 48 and 72 h as shown (Supplementary Figure 1A ), and 20 mg/ml Onconase significantly reduced the invasive capacities of H2595, H2373 and H2591 cells (Supplementary Figure 1B) . By contrast, control cells demonstrated a twofold increase in cell number at 48 h and a threefold increase at 72 h. Similar effects were seen with 5-10 mg/ml Onconase at 48 and 72 h, but to a lesser extent than seen with treatment at 20 mg/ml (Supplementary Figure 2) . Reverse transcription-PCR (RT-PCR) validation of ABCB1 and NFKB(p50 subunit) in all the three cell lines showed decreased levels of their expression by Onconase treatment at 48 and 72 h (Supplementary Figure 3) . These findings were validated at protein levels by western blotting (Supplementary Figure 4) .
MiRNAexpression
Mirs that were influenced by Onconase treatment are seen in Table 1 , and the associated Heatmap (Figure 1 ). Hsa-miR-17* and hsa-miR-30c demonstrated the most significant changes in miRNA expression following Onconase treatment across cell lines and were selected for further study based on these data. Treatment with Onconase at 20 mg/ml for 72 h resulted in upregulated expression of hsa-miR-17* by 30-fold compared with controls (Pp10
À8
) and downregulated expression The mirs that are discussed in the paper are highlighted in bold.
Ranpirnase, NFKB and mesothelioma CM Goparaju et al Figure 1 Heat map of miRNA expression with Onconase treatment of mesothelioma cell lines. Control conditions are seen in the upper panels and dose and time changes are seen in the lower panels.
Ranpirnase, NFKB and mesothelioma CM Goparaju et al of hsa-miR-30c by 41% in cell lines compared with controls (Pp10 À8 ) based on results obtained from the miRNA arrays. These miRNA array results from Onconase treatment were validated by RT-PCR. A dose-dependent effect of Onconase on the expression of these miRs was seen (Figure 2 ). Hsa-miR-17* had minimal native expression in the mesothelioma cell lines studied and was upregulated 2.46-3.23-fold by treatment with 20 mg/ml Onconase. Conversely, hsa-miR-30c has high endogenous expression in the absence of Onconase and was downregulated 61-63% following treatment with Onconase.
Transfection and functional assays
We were successful in transfecting hsa-miR 17* mimic and hsa-30c inhibitor in all the three cell lines ( Figures  3a and b) . Hsa-miR-17* mimic transfection decreased cell invasion by 31-48% in all cell lines (Pp0.004) compared with controls, whereas hsa-30c inhibitor expression decreased cell invasion by 81-96% in all cell lines (Pp0.001) compared with controls ( Figure 4a ). Scratch closure assay demonstrated a similar trend, with significant reduction in closure with expression of the hsa-miR-17 mimic (Pp0.005) and hsa-miR-30c inhibitor (Po0.001) (Figure 4b ). Anchorage-independent growth was reduced 31-47% by hsa-miR-17* mimic expression compared with controls (Po0.004) and 32-46% by hsa-miR-30c inhibitor expression compared with controls (Po0.001) (Figure 4c ). Cell proliferation assay also demonstrated a similar effect, with 25-33% reduction in cell number following forced expression of hsa-miR-17* mimic (Pp0.004) and a 35-80% reduction with forced expression of hsa-miR-30c inhibitor (Pp0.001) (Figure 4d ). Overall, forced expression of both the hsa-miR-17* mimic and hsa-miR-30c inhibitor resulted in a significant decrease in functional activity in all the four assays with each of the three MPM cell lines. Conversely, cell invasion results were reversed when the cells were forcibly expressed with hsa-miR-17* inhibitor and hsa-miR-30c mimic ( Figure 5 ). These data with the two miRNAs are consistent with the effects that Onconase itself had on proliferation and invasion, and suggest that miR-17* has tumor suppressor properties while miR-30c may, in fact, stimulate oncogenic properties of mesothelioma cell lines (Saxena et al., 2002) .
ABCB1, ABCC1 NFKb and downstream targets of NFKb expression
RT-PCR demonstrated that the forced expression of hsa-miR-17* mimic and hsa-miR-30c inhibitor reduced the expression of ABCB1 and NFKB1 compared with controls ( Figure 6a ), and we validated this finding by western blotting (Figure 6b ). Overall, a recapitulation of decreased expression of these two genes with Onconase incubation was seen with the forced expression of a hsa-miR-17* mimic and hsa-miR-30c inhibitor (Supplementary Figure 3) .
Reporter assay and miRNA-binding assays In RT-PCR and western blot analysis, forced expression of miR-17* mimic and miR-30c inhibitor decreased the NFK and ABCB1 levels at both mRNA and protein.
To further demonstrate whether these miRNAs truly target endogenous NFKb(p50) and ABCB1, we cotransfected HEK 293T cells with miRNAs and reporter plasmids. Luciferase assays indicated that the introduction of hsa-miR-17* mimic significantly (P ¼ 0.004) decreased the luciferase activity of NFK to 58% compared with negative control (Figure 7 ). This reduced luciferase activity after hsa-miR-17* mimic transfection provides evidence that the miRNA under study is directly involved in the regulation of NFK gene. Introduction of hsa-miR-30c mimic showed no effect on NFKb luciferase reporter. On the other hand, transfection of hsa-miR-17* mimic and hsa-miR-30c inhibitor had no effect on ABCB1 indicating that these miRs have an indirect effect on ABCB1 gene regulation possibly through other targets (Figure 8) .
RT-PCR evaluation of survival genes downstream of NFKb including BCL-xL, cIAP1, as well as another known target influencing cellular potential for invasion Figure 2 Dose effect of Onconase on expression of hsa-mir-17*, which increased in a dose-dependent manner, and has-mir-30c, which decreased similarly in a dose-dependent manner. Relative expression levels relative to PPIA for each cell line and each miRNA are seen below. (MMP9, gelatinase B), revealed decreased expression of these genes with hsa-miR-17* mimic and hsa-miR-30c inhibitor transfection ( Figure 9 , Supplementary Figure  5) . From these data, we deduce that Onconase treatment affects these specific miRNAs, which are involved in downstream regulation of pathways responsible for the malignant behavior of these cell lines.
Discussion
Onconase, a homolog of bovine pancreatic ribonuclease (RNase A), exerts its biological effect through selective cleavage of intracellular tRNA phosphodiester bonds and inhibition of protein synthesis (Halicka et al., 2002; Saxena et al., 2002; Singh et al., 2007) . In addition, Onconase selectively alters expression of genes involved in cell-cycle regulation and programmed cell death; with decreased expression of BCL-2 (antiapoptotic) and upregulation of BAX (pro-apoptotic) expression in vitro . Onconase's unique biochemical structure and unusually high conformational stability lends itself to enhanced intracellular survival and restricted inactivation by native cytoplasmic ribonuclease inhibitors (Kobe and Deisenhofer, 1996; Dickson et al., 2005) . These properties result in significant cytostatic and cytotoxic activity against various human tumors in both in vitro and in vivo models (Beck et al., 2008) . In vitro studies have demonstrated Onconase's efficacy as a single agent in lung cancer models with selective tumor cell death and preservation of surrounding normal cells (Lee, 2008) . These data also correlate with studies that demonstrate Onconase-specific inhibition of cell growth in human malignancies such as lung, colorectal, breast and esophageal carcinoma Lee et al., 2007; Beck et al., 2008) . Onconase also exhibits synergistic properties with various chemotherapeutic agents in vitro (Beck et al., 2008) , but a mechanism for its chemosensitizing abilities has never been elucidated. MiRNAs are important functional RNA units, 21-23 nucleotides in length, which have a selective capacity to regulate gene expression, enzymatic activity and regulatory cell functions by interfering with mRNA transcription and translation (Ambros, 2004) . MiRNAs exist in short stem-loop structures called pre-miRNA, and are processed into mature functional miRNA species within the cell cytoplasm (Ambros et al., 2003) . Mature miRNA molecules are complementary to one or more mRNA molecules, and can interfere with translation by restricting ribosomal progression (Ambros, 2004; Wang et al., 2004) . Selective miRNA expression is thought to be important for cancer cell transformation and survival by downregulating of specific gene products that are important for cell-cycle regulation and programmed cell death (Bartel, 2004) . Expression profiles associated with a variety of human malignancies have characterized over 200-300 different regulatory miRNAs, however, less than 10% of those characterized have been specifically correlated with a particular pathway or mechanism of function (Ambros, 2004) .
In our study, Onconase caused dose-specific inhibition of proliferative and invasive properties of mesothelioma cells. Hsa-miR-17* and hsa-miR-30c, the two Figure 7 Reporter assay for effects of hsa-mir-17* and has-mir30c on NFKB. Hsa-miR-17* mimic significantly (P ¼ 0.004) decreased the luciferase activity of NFKb compared with negative control (and the effect was completely reversed with the addition of the miRNA inhibitor. Introduction of hsa-miR-30c mimic showed no effect on NFKb luciferase reporter. Kasashima et al., 2004) . These miRNAs were initially isolated from murine tumor cells, and then have been identified in a variety of human malignancies. However, to date no functional data have been reported to suggest specific behaviors or mechanisms by which these miRNAs regulate gene expression. Our demonstration of Onconase-mediated changes in miRNA expression profiles, with significant upregulation of hsa-miR-17* and downregulation of hsa-miR-30c paired with decreased malignant activity in MPM cell lines forced to overexpress hsa-miR-17* mimic and hsamiR-30c inhibitor, is the first to implicate these miRNAs in MPM. Moreover, the downstream miRNA's targets that regulate gene expression and alter cellular behavior following Onconase treatment have not been previously described.
NFKb has a key role in asbestos-induced malignant transformation. Asbestos-induced malignant transformation of mesothelial cells is due to induction of a profound inflammatory reaction, phagocytosis of fibers with subsequent macrophage differentiation and the release of numerous cytokines and reactive oxygen species that are mutagenic (Robledo and Mossman, 1999) . In vitro models evaluating the impact of asbestos on cell-cycle regulation and survival have discovered a significant relationship between activation of NFKb pathways and cellular protection from asbestos-induced cell death (Yang et al., 2006 . This effect has been verified by selective inhibition of NFKb, which subjects the exposed cells to programmed cell death (Yang et al., 2006) . NFKb is a regulatory transcription protein complex that mediates a variety of cellular and inflammatory processes involved in cellular stress, apoptosis and malignant transformation (Gilmore, 1999) . Downregulation of NFKb reduces tumorigenic properties of malignant epithelial cells, and has been demonstrated in both in vivo and in vivo models to be an important component in molecular pathways that involve tumor cell invasion (Barnhart and Peter, 2003; Gilmore, 2003 Gilmore, , 2006 Micheau and Tschopp, 2003) . To date, specific miRNAs that mediate NFKb expression and reduce the invasive potential of malignant cells have not been described. We have demonstrated a direct relationship between Onconase-mediated hsa-miR-17* upregulation and the expression of NFKB1 that encodes an NFKb subunit p50 in three MPM cell lines. We have also demonstrated that forced overexpression of these miRNAs result in decreased malignant behavior observed in cell lines evaluated by in vitro functional assays because of the selective downregulation of cell-survival genes and those associated with increased invasion. Therefore, we believe Onconase has a specific effect on NFKb and that hsa-miR-17* and hsa-miR-30c are specifically relevant intermediates in this pathway. Proof for this hypothesis is demonstrated with our data in mesothelioma cell lines, which investigate important cell-survival genes downstream from NFKb. Soini (Soini et al., 1999) has reported that all mesothelioma cell lines are positive for bcl-X, and other investigators have demonstrated that introduction of antisense oligonucleotides specific to Bcl-xL mRNA can sensitize MPM cells to chemotherapeutic agents (Cao et al., 2007) . Additionally, the growth of established mouse flank human tumor xenografts is reduced with intratumor administration of antisense oligoncleotides to BCL-x (Littlejohn et al., 2008) . Another NFKb target, IAP1, is overexpressed in the disease (Gordon et al., 2007; Symanowski et al., 2009) and is responsible for a large degree of the resistance of cultured MPM cells to cisplatin. As detailed above, miR-17c* and inhibitor of miR-30 suppressed expression of these genes in our MPM cell lines, possibly explaining enhanced sensitivity of chemotherapy drugs when used in combination with Onconase.
Another challenge in the development of novel chemotherapeutic treatments is the phenomenon of multidrug resistance by tumor cells, a process which most commonly occurs by upregulation of ATP-binding cassette (ABC) transporters. ABC transporters facilitate translocation of a variety of substrates across the cell membrane, including metabolic products and exogenous substrates such as chemotherapy drugs, providing a protective mechanism for malignant cells (Davidson et al., 2008) . Structural domains specific to ABC transmembrane proteins that facilitate movement of hydrophobic solutes common to many chemotherapeutic agents have been a focus of study (Jones and George, 2004, 2004) . Inhibition of ABC transporters has been proven to be an efficacious technique for improvements in cancer therapy, and currently tyrosine kinase inhibitors are being investigated because of their preferential inhibition of these multidrug resistant transmembrane proteins (Shi et al., 2007 (Shi et al., , 2009 Shukla et al., 2009 ). ABCB1 and ABCC1, two structurally similar ABC transporters, have been previously implicated in chemotherapy resistance in human malignancies (O'Donnell et al., 2005; Gillet et al., 2007) . Our work demonstrates high native expression of multidrug resistance genes in MPM and agrees with previous data regarding ABC transporters and MPM (Khokhar et al., 2001; Soini et al., 2001) . Onconase treatment significantly decreased expression of ABCB1 in cell lines, which natively expressed those ABC transporters, and the effect of Onconase-associated microRNAs is not a direct effect on ABCB1. It is curious that the only subgroup exhibiting benefit of Onconase in the recent randomized trial were those Onconase-treated patients who had received previous cytotoxic chemotherapy. These results require validation in a larger clinical study but the mechanism for these findings could be related to miRNA-induced effects on NFKb.
Aggressive protocols of combination chemotherapy with or without targeted therapies are likely the direction of future cancer therapy. Our data suggest that Onconase may significantly enhance the biological activity of additional chemotherapeutic treatments through diverse mechanisms, making it an ideal agent for multidrug therapies. The full therapeutic potential of Onconase may also be realized by exploiting its distinctive structural and functional features to produce more powerful variants or novel antitumor drugs.
Materials and methods

Cell lines
Mesothelioma cell lines H2373, H2591 and H2595 were maintained in 1ÂDulbecco's modified eagle medium (DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen). Mesothelioma cell lines in this study were established in our laboratory from the surgical specimens of Dr Harvey I Pass as described (Pass et al., 1995) .
Onconase treatment
Cells were plated at a density of 2 Â 10 6 cells/plate in 10-cm plates in duplicates. Cells in culture were treated with 0, 1.25, 2.5, 5, 10 or 20 mg/ml Onconase (Alpha Cell Corporation, Paramus, NJ, USA) for 48 and 72 h.
RNA isolation and miRNA expression profiles
MiRNA-enriched RNA was isolated from treated and untreated cultured cells using mirVANA miRNA isolation kit (Ambion, Foster City, CA, USA). MiRNA expression profiles generated on OSUCCC microarrays were quantiles normalized, analyzed as previously reported (19) at Ohio State University and sorted for significance.
RT-PCR
From the miRNA expression miRs with the greatest fold change and highest significance, hsa-miR-17* and hsa-miR-30c were selected for further study. RT-PCR validation of onconase effect on the expression of hsa-miR-17* and hsamiR-30c was performed using stem-loop PCR technology (Chen et al., 2005; Varkonyi-Gasic et al., 2007) (56, 57) . MiRNA sequences are obtained from miRbase (http:// www.mirbase.org). The stem-loop technique involves a reverse-transcription step to synthesize artificial complementary DNA of the miR followed by PCR amplification. Reverse transcription was accomplished with initial incubation at 16 1C for 30 min followed by gradual annealing and extension for 60 cycles at 30 1C for 30 s, 42 1C for 30 s and 50 1C for 30 s and a final extension at 85 1C for 5 min using SuperScript II reverse transcriptase kit (Invitrogen) using miR-specific stem-loop RT primers. PCR amplification was carried out in a total volume of 20 ml using the Clontech Advantage 2 PCR kit (Clontech, Mountain View, CA, USA) and optimized concentrations of MgCl 2 . The reactions were performed with denaturing for 15 s at 94 1C annealing for 30 s at 57 1C and elongation for 30 s at 70 1C for a total of 35 cycles; the final extension at 72 1C for 5 min. RT-PCR products were analyzed on 4% MetaPhor agarose (Lonza, Rockland, ME, USA) gels.
For hsa-miR-17*, 5 0 -GTCGTATCCAGTGCAGGGTCCG AGGTATTCGCACTGGATACGACACCTACAAGTGCC-3 0 stem-loop RT primer was used for reverse transcription, and 5 0 -ACTGCAGTGAAGGCAC-3 0 (sense) and 5 0 -GTGCAGG GTCCGAGGT-3 0 (antisense) primers were used for PCR amplification. For hsa-miR-30c, 5 0 -GTCGTATCCAGTGCA GGGTCCGAGGTATTCGCACTGGATACGACACGCTG AGAGTGT-3 0 stem-loop RT primer was used for reverse transcription, and 5 0 -GCGTGTAAACATCCTACAC-3 0 (sense) and 5 0 -GTGCAGGGTCCGAGGT-3 0 (antisense) primers were used for PCR amplification. The amplification of peptidylprolyl isomerase A (PPIA) with primers 5 0 -TCTGAG CACTGGAGAGAAAGG-3 0 (sense) and 5 0 -GGAAAACAT GGAACCC-3 0 (antisense) served as controls for equal loading and integrity of all PCR experiments.
Quantification of RT-PCR products
The RT-PCR products were analyzed on 4% MetaPhor agaose gels and the images were captured using Kodak Imaging System 4000MM (Molecular Imaging, Woodbridge, CT, USA). Relative signal intensities were quantified using Kodak Molecular Imaging Software V4.04. The relative expression levels were normalized to the loading control, PPIA.
MiR oligonucleotides and transfections
Oligonucleotides miRIDIAN hsa-miR-17* mimic (C-300486-05) and hsa-miR-30c inhibitor (IH-300542-07) were purchased from Dharmacon RNAi Technologies (Lafayette, CO, USA). Standard Lipofectamine2000 (Invitrogen) protocol was followed as recommended to transfect miRNA. Briefly, cells plated at 80-90% confluency were incubated in antibiotic free DMEM media for 1 h and then 40 nM of miRIDIAN miR-17* mimic or miR-30c inhibitor was complexed with lipofectimine and introduced into H2373, H2591 and H2595 cells. Transfected cells were incubated for 48 h. For negative control, cells were transfected with scrambled oligo (CN-001000-01-05, Dharmacon RNAi Technologies). Pooled populations of transfected cells were assayed for proliferation, scratch assay, matrigel cell invasion and soft agar colony formation. Hsa-miR-17* mimic and hsa-miR-30 inhibitor expression in transfected cells was verified using stem-loop RT-PCR technology as described above.
Cell proliferation assay A total of 3000 cells from each experimental cell line were plated in flat bottom 96-well plates in 100 ml DMEM and 10% FBS in six replicates and incubated at 37 1C for 48 h. A volume of 20 ml of Cell Titer-Blue reagent (Promega, Madison, WI, USA) was added to each well and incubated for 3 h at 37 1C and 5% CO 2 . Proliferation was assessed by optical density (OD) values measured at 560/590l using a universal plate reader (Universal Reader Victor; PerkinElmer Life and Analytical Sciences, Waltham, MA, USA).
Scratch assay (wound closure assay)
A day before the experiment, 2 Â 10 5 cells/well was seeded in six-well plates. Using a 1 ml pipette tip, three vertical linear scratches were made per well. Cells were washed with 1 Â phosphate-buffered saline and medium was changed. Plates were marked with a fine pen. Scratch widths (six measurements per well) were measured using a light microscope at zero and 24 h. The percent of the scratch closure was calculated.
Matrigel cell invasion assay
Cell invasion assay was performed using the BD Biocoat Matrigel Invasion Chambers (BD Biosciences, Franklin Lakes, NJ, USA) according the manufacturer's protocol. One million cells were seeded onto the inserts (8-mM pore sized polycarbonate membrane) coated with a thin layer of Matrigel Basement Membrane Matrix (BD Biosciences) diluted at 1:100 in phosphate-buffered saline. The plates were incubated for 48 h at 37 1C and 5% CO 2 . Cells that invaded the Matrigel matrix to the lower surface of the membrane were fixed and stained with Giemsa solution and counted under a light microscope. Eight fields in four separate quadrants of each membrane were counted and averaged. The assay was performed in triplicates.
Soft agar colony formation assay Base agar was prepared 30 min before cell plating by mixing equal volumes of 1% agarose at 40 1C and pre-warmed 2 Â DMEM with 10% FBS, poured onto a six-well plate (1.5 ml per well), and allowed to polymerize. The top agar was made by mixing equal volumes of warm 0.7% agarose and 2 Â DMEM with 10% FBS (total volume 2 ml per well), combined with 5000 cells from each experimental cell line. Top agar was poured onto the base agar and plates were incubated at 37 1C and 5% CO 2 for 21 days. Colonies were stained with 0.5 ml of 0.005% Crystal Violet for 1 h and counted using a dissecting microscope.
NFKB1(p50), ABCB1 and BCL2L1 expression assessment NFKB1, ATP-binding cassette transporters B1 (ABCB1) and pro-survival BCL-2 homolog (BCL2L1) were assessed in all native cell lines, Onconase-treated cell lines and cell lines with forced expression of the hsa-miR-17* mimic and hsa-miR-30c inhibitor using primers designed from Dharmacon RNAi Technologies. For NFKB1, the resulting primers, 5 0 -CCATAT TTGGGAAGGCCTGAA-3 0 (sense) and 5 0 -TGGTCCCACA TAGTTGCAGA-3 0 (antisense), amplify a 264-bp product. For ABCB1 RT-PCR, the resulting primers, 5 0 -CCATATTT GGGAAGGCCTGAA-3 0 (sense) and 5 0 -TGGTCCCACAT AGTTGCAGA-3 0 (antisense), amplify a 157-bp product. For BCL2L1, 5 0 -GGAGCCACTGGCCACAGCAG-3 0 (sense) and 5 0 -ATCCCAGCCGCCGTTCTCCT-3 0 (antisense), amplify a 368-bp product. For cIAP-1, 5 0 -GCCGGGGTGCCTGTCTC AGAA-3 0 (sense) and 5 0 -ACCACAGGCAAAGCAGGCTA CC-3 0 (antisense), amplify a 500-bp product. For MMP9, 5 0 -A AGCTGGACTCGGTCTTTGA-3 0 (sense) and 5 0 -TCAACTC ACTCCGGGAACTC-3 0 (antisense), amplify a 370-bp product. The reactions were performed as previously described. RT-PCR products were subjected to electrophoresis on 2% Tris-acetate EDTA agarose gel.
Western blot analysis
Total cell proteins were prepared by lysing the cells in 10 mM/l Tris (pH 7.5), 1 mM/l EDTA, 150 mM/l NaCl, 1% Triton X-100, 1 mM/l DTT, 10% glycerol for half-hour on ice. The lysates were centrifuged and cleared at 13 K and total protein was estimated by BCA Protein assay kit (Thermoscientific, Rockford, IL, USA). A measure of 30 mg of samples were separated on 8-16% Tris-Glycine gel (Invitrogen) and transferred to PVDF membrane (Millipore, Bedford, MA, USA). Membranes were blocked in 5% non-fat dry milk for 1 h at room temperature followed by incubation in primary antibody for overnight at 4 1C. The membrane was then incubated in secondary antibody conjugated with horseradish peroxidase for 1 h at room temperature and were developed using the SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA). To ensure equal loading and transfer of proteins, membranes were stripped and reprobed with ERK2 antibody. Mouse monoclonal Mdr-1 (ABCB1; sc-5551C), rabbit polyclonal NFkB (sc-372) and ERK2 (sc-154) were purchased from Santa Cruz Biotechnologies, Inc, Santa Cruz, CA, USA.
Luciferase assays for MicroRNA target sequences Luciferase assays were carried out in HEK 293T cells to determine the effect of miRNAs, hsa-miR-17* and hsa-miR30c mimic on the activity of NFKb and ABCB1. The luciferase reporters, pEZX-Luc-NFKb-3 0 -UTR, pEZX-Luc-ABCB1-3 0 -UTR and Luc-control plasmids were purchased from GeneCopoeia (Rockville, MD, USA). HEK 293T cells were transfected using lipofectamine 2000 (Invitrogen) following manufacturer's protocol. In brief, cells were seeded at 70% confluence in a 24-well plate and then transfected with 0.8 mg of DNA constructs along with 40 nM of miRNA Oligo's. The cells were transferred to a 96-well plate 18 h after transfection and cultured for another 24 h. Luciferase activity was measured by luciferase assay kit (GeneCopoeia) with Lumistar Galaxy (BMG Lab Technologies, Cary, NC, USA) Renilla luciferase was used for normalization. All the experiments were carried out in triplicates.
Statistical analysis
Bivariate correlations Pearson's coefficient and students twosided T-tests were used to determine significance, which was reported as significant for Po0.05. All assays were performed in triplicates and statistical evaluations were performed using the SPSS software package (SPSS, Chicago, IL, USA, v.12). All values in the text and figures represent the means±stan-dard deviation.
